 Home > Medical News > Medicines Company News > Hengrui Medicine SHR8008 capsules and HRS2543 tablets were approved for clinical trials

Hengrui Medicine SHR8008 capsules and HRS2543 tablets were approved for clinical trials

 Last Update: 2021-05-02
 Source: Internet
 Author: User

Tags

tigan drug

iodine phase diagram

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 6, Hengrui Medicine issued an announcement stating that the company and eVENUSPHARMACEUTICAL LABORATORIES INC.

SHR8008 Capsules will carry out a randomized, double-blind, double-simulated, fluconazole parallel controlled, multi-center phase III clinical study on the effectiveness and safety of the treatment of acute vulvovaginal candida disease (VVC) (plan number: SHR8008- 302).

SHR8008 is a new type of oral azole antifungal drug that can highly specifically inhibit the fungal CYP51 enzyme.

HRS2543 tablets will carry out clinical trials for the treatment of advanced malignant tumors.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.